Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Comparative Effectiveness Infrastructure Is Priority, Federal Advisors Say

Executive Summary

Both the Institute of Medicine and the Federal Coordinating Council for Comparative Effectiveness Research are placing a high priority on building an infrastructure around comparative effectiveness to facilitate the research as well as the dissemination of findings

Related Content

PCORI Initiates A Targeted Approach To Research At November Meeting
PCORI Should Consider Health IT In Setting Research Priorities – Board’s Weisman
Stimulus-Funded CER: Few Awards Are For Drug Vs. Drug Studies
Large Payers, Including CMS, PBMs, Mostly Absent From PCORI Board
NIH Comparative Effectiveness Funding Covers Wide Range Of Subjects
Mammogram Recommendations Show Perils Of Communicating CER Results
AHRQ To Put More Than Half Of Stimulus CER Funding To Evidence Generation
Comparative Effectiveness Needs To Be More Than Drug Vs. Drug - NEJM
Comparative Effectiveness Council Urges Infrastructure Improvements
Baucus Comparative Effectiveness Proposal Runs Into Roadblock From Senior Republicans





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts